BTIG Maintains Buy on Bionano Genomics, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro maintains a Buy rating on Bionano Genomics (NASDAQ:BNGO) but lowers the price target from $3 to $2.
May 18, 2023 | 11:49 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Bionano Genomics' price target has been lowered from $3 to $2 by BTIG analyst Mark Massaro, who maintains a Buy rating.
The news of BTIG analyst Mark Massaro maintaining a Buy rating on Bionano Genomics (BNGO) is positive for the stock. However, the lowering of the price target from $3 to $2 may create some uncertainty among investors, potentially offsetting the positive impact of the Buy rating. As a result, the short-term impact on BNGO's stock price is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100